Compare · MYGN vs ORKA
MYGN vs ORKA
Side-by-side comparison of Myriad Genetics Inc. (MYGN) and Oruka Therapeutics Inc. (ORKA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MYGN and ORKA operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- ORKA is the larger of the two at $5.15B, about 12.1x MYGN ($425.0M).
- MYGN has been more active in the news (17 items in the past 4 weeks vs 14 for ORKA).
- MYGN has more recent analyst coverage (23 ratings vs 11 for ORKA).
- Company
- Myriad Genetics Inc.
- Oruka Therapeutics Inc.
- Price
- -
- -
- Market cap
- $425.0M
- $5.15B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1995
- News (4w)
- 17
- 14
- Recent ratings
- 23
- 11
Myriad Genetics Inc.
Myriad Genetics, Inc., a molecular diagnostic company, develops and markets predictive, personalized, and prognostic medicine tests in the United States and internationally. The company offers myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; and riskScore, a personalized medicine tool. It also provides BRACAnalysis CDx, a DNA sequencing test for use in identifying ovarian and HER2 negative metastatic breast cancer patients with deleterious or suspected deleterious germline; GeneSight, a DNA genotyping test to aid psychotropic drug selection for depressed patients; and Vectra, a protein quantification test for assessing the disease activity of rheumatoid arthritis. In addition, the company offers Foresight, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; Prequel, a non-invasive prenatal screening test to screen for severe chromosomal disorders in a fetus; and Prolaris, a RNA expression test for assessing the aggressiveness of prostate cancer. Further, it provides EndoPredict, a RNA expression test for assessing the aggressiveness of breast cancer; myPath Melanoma, a RNA expression test for diagnosing melanoma; and myChoice CDx, a companion diagnostic to measure three modes of homologous recombination deficiency comprising loss of heterozygosity, telomeric allelic imbalance, and large-scale state transitions in cancer cells. Additionally, the company offers biomarker discovery, and pharmaceutical and clinical services to the pharmaceutical, biotechnology, and medical research industries; and operates an internal medicine emergency hospital primarily for internal medicine and hemodialysis. It has a a strategic collaboration with Illumina, Inc. Myriad Genetics, Inc. was founded in 1991 and is headquartered in Salt Lake City, Utah.
Latest MYGN
- President and CEO Raha Samraat S. was granted 3,542 shares, increasing direct ownership by 0.33% to 1,068,083 units (SEC Form 4)
- Chief Commerical Officer Donnelly Brian J was granted 5,000 shares, increasing direct ownership by 0.88% to 573,363 units (SEC Form 4)
- Director Kumar Rashmi sold $66,843 worth of shares (15,000 units at $4.46) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 171,889 units (SEC Form 4)
- Director Skovronsky Daniel was granted 59,701 shares, increasing direct ownership by 44% to 195,507 units (SEC Form 4)
- Director Newcomer Lee Nisley was granted 59,701 shares, increasing direct ownership by 45% to 191,842 units (SEC Form 4)
- Director Davis Mark Steven was granted 59,701 shares, increasing direct ownership by 127% to 106,665 units (SEC Form 4)
- Director Phanstiel S. Louise was granted 59,701 shares, increasing direct ownership by 21% to 341,652 units (SEC Form 4)
- Director Dreismann Heinrich was granted 59,701 shares, increasing direct ownership by 35% to 231,145 units (SEC Form 4)
- Director Reitan Colleen F was granted 59,701 shares, increasing direct ownership by 65% to 152,030 units (SEC Form 4)
- Director Bisaro Paul was granted 59,701 shares, increasing direct ownership by 61% to 157,142 units (SEC Form 4)
Latest ORKA
- Senior Vice President, Finance Agarwal Arjun sold $128,468 worth of shares (1,587 units at $80.95) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 15,312 units (SEC Form 4)
- Senior Vice President, Finance Agarwal Arjun exercised 9,459 shares at a strike of $15.88 and sold $687,035 worth of shares (9,854 units at $69.72) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 16,899 units (SEC Form 4) to cover taxes
- Chief Medical Officer Goncalves Joana sold $550,607 worth of shares (7,947 units at $69.28) as part of a pre-agreed trading plan and exercised 7,000 shares at a strike of $7.32, decreasing direct ownership by 3% to 32,718 units (SEC Form 4) (withholding tax)
- Chief Executive Officer Klein Lawrence Otto sold $120,494 worth of shares (1,729 units at $69.69), decreasing direct ownership by 0.19% to 925,580 units (SEC Form 4) to cover taxes
- Chief Operating Officer Sandler Laura Lee sold $41,814 worth of shares (600 units at $69.69), decreasing direct ownership by 0.25% to 236,384 units (SEC Form 4) (for tax liability)
- General Counsel Quinlan Paul T sold $51,083 worth of shares (733 units at $69.69), decreasing direct ownership by 2% to 31,034 units (SEC Form 4) (for withholding tax)
- Director Dambkowski Carl sold $2,454,382 worth of shares (35,000 units at $70.13) as part of a pre-agreed trading plan, decreasing direct ownership by 47% to 38,743 units (SEC Form 4)
- Oruka Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- SEC Form 4 filed by Director Dambkowski Carl
- SEC Form 4 filed by Director Kulkarni Samarth